What is Haemonetics's investing cash flow?

Haemonetics (HAE) reported investing cash flow of -$86.61M in Q1 2026.

What is the long-term trend for Haemonetics's investing cash flow?

Over 3 years (2022 to 2026), Haemonetics's investing cash flow has grown at a 27.6% compound annual growth rate (CAGR), from -$86.35M to -$179.55M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Haemonetics HAE Investing Cash Flow

Investing Cash Flow at other companies

AbbottABT

-$20.32B-4,224%

TFX

TeleflexTFX

-$74.79M-160%

Boston ScientificBSX

-$591M-18.2%

MedtronicMDT

-$917M-87.1%

LivaNovaLIVN

-$14.58M-37.2%

ICU MedicalICUI

-$11.21M+33.3%

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's investing cash flow?: Haemonetics (HAE) reported investing cash flow of -$86.61M in Q1 2026.
What is the long-term trend for Haemonetics's investing cash flow?: Over 3 years (2022 to 2026), Haemonetics's investing cash flow has grown at a 27.6% compound annual growth rate (CAGR), from -$86.35M to -$179.55M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.